Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura

Kristi L. Bengtson, Michael A. Skinner, Russell E. Ware

Research output: Contribution to journalArticle

20 Scopus citations


Thrombocytopenia with life-threatening hemorrhage in childhood immune thrombocytopenic purpura is rare, but effective therapeutic options are limited for the patient with bleeding. We report the efficacy of humanized anti-CD20 monoclonal antibody (rituximab, Rituxan) therapy for an infant with severe, refractory life-threatening immune thrombocytopenic purpura.

Original languageEnglish (US)
Pages (from-to)670-673
Number of pages4
JournalJournal of Pediatrics
Issue number5
Publication statusPublished - Nov 2003


ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this